PARIS, Oct. 21, 2024 /PRNewswire/ — Okomera pronounces Bpifrance funding to develop and standardize novel CRISPR screening assay to speed up drug discovery in oncology with main most cancers analysis middle of Marseille, CRCM.
Raphael Tomasi, CTO & Co-Founding father of Okomera
Okomera is creating desktop platform for automated organoid screening utilizing droplet-microfluidics and AI to speed up drug discovery. Their patented tech developed after 10 years of analysis at Pasteur Institute and Ecole Polytechnique, supplies Multiplexing, Co-culture and Excessive-throughput screening of drug candidates on miniaturized Affected person Derived Organoids (PDOs).
“We’re honored to obtain this grant from Bpifrance,” mentioned Sidarth Radjou, CEO of Okomera.
Dr. Thomas Miller, Principal Investigator at IPC and CRCM, emphasised the importance of this collaboration: “This partnership is a unprecedented alternative to advance our understanding of most cancers biology. By creating and standardizing a CRISPR screening assay that may be straight utilized to PDOs, we are able to create extra correct illness fashions. This is not going to solely enhance our means to review most cancers mechanisms but in addition improve {our capability} to determine new therapeutic targets and develop more practical therapies.”
“We’re thrilled to embark on this collaboration, because it affords an unprecedented alternative to leverage cutting-edge applied sciences in most cancers analysis,” mentioned Dr. Geraldine Guasch, Analysis Director Inserm at CRCM and Scientific Director of the 3D-HUB-O organoid platform. “By integrating CRISPR know-how with Okomera’s superior organoid screening platform, we’re setting the stage for extra exact and efficient therapeutic methods. This venture represents a big step ahead in translating scientific discoveries into tangible scientific functions, finally bringing us nearer to enhancing outcomes for most cancers sufferers.”
Corentin Molson, representing Bpifrance, commented: “Bpifrance is proud to help Okomera on this pioneering effort. Their progressive method to creating and standardizing CRISPR screening on PDOs displays our dedication to fostering innovation in healthcare. This venture has the potential to make vital contributions to the sector of precision drugs and enhance outcomes for most cancers sufferers.”
We might additionally like to acknowledge the contribution and help supplied by AstraZeneca to help the profitable grant software.
About Okomera, go to our web site: www.okomera.com
Paoli-Calmettes Institute: Based mostly in Marseilles, Paoli-Calmettes Institute (IPC) is the primary most cancers complete centre in area offering international take care of most cancers. It’s a member of the nationwide federation Unicancer. Additional info: www.institutpaolicalmettes.fr
Photograph – https://mma.prnewswire.com/media/2534892/Okomera_co_founder.jpg
Brand – https://mma.prnewswire.com/media/2534893/Okomera_Logo.jpg
Okomera_Logo
Contact: Sidarth Radjou, CEO sidarth.radjou@okomera.com
Cision
View authentic content material:https://www.prnewswire.co.uk/news-releases/okomera-gets-1-5-million-grant-to-develop-microfluidics–ai-powered-crispr-editing-platform-for-target-validation-302280663.html
This articles is written by : Nermeen Nabil Khear Abdelmalak
All rights reserved to : USAGOLDMIES . www.usagoldmines.com
You can Enjoy surfing our website categories and read more content in many fields you may like .
Why USAGoldMines ?
USAGoldMines is a comprehensive website offering the latest in financial, crypto, and technical news. With specialized sections for each category, it provides readers with up-to-date market insights, investment trends, and technological advancements, making it a valuable resource for investors and enthusiasts in the fast-paced financial world.